Collins Helen Louise 4

4 · Enliven Therapeutics, Inc. · Filed Feb 19, 2026

AI-generated summary of this filing

Updated Feb 19, 2026

Enliven (ELVN) CMO Helen Collins Exercises Options, Sells 45k Shares

What Happened

Helen Collins, Chief Medical Officer of Enliven Therapeutics, exercised options and sold the resulting 45,000 shares on February 17, 2026. She exercised the option at $2.48 per share (cost $111,600) and sold the 45,000 shares in the open market at a weighted average price of $26.17 for total gross proceeds of $1,177,862. The net difference before fees and taxes is roughly $1,066,262. The filing also reports the derivative exercise/disposition mechanics associated with the option.

Key Details

Transaction date: 2026-02-17 (Form 4 filed 2026-02-19 — timely filing).
Option exercise: 45,000 shares acquired at $2.48 per share (total $111,600).
Sale: 45,000 shares sold at weighted average $26.17 (range $25.76–$26.695) for $1,177,862 (multiple trades; weighted average reported).
Shares owned after transaction: not specified in this filing.
Footnotes: Transactions were executed under a Rule 10b5-1 trading plan adopted Oct 19, 2025; all option shares were fully vested and exercisable as of the date of exercise; seller can provide breakdown of individual trade prices upon request.

Context

This is an option exercise followed by an immediate sale (a cashless-style outcome): the insider exercised vested options and sold the acquired shares the same day under a pre-established 10b5-1 plan. Such sales under a trading plan are typically pre-planned and do not necessarily indicate a change in the insider’s view of the company.

Form 4

Period: 2026-02-17

CHIEF MEDICAL OFFICER

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-17$2.48/sh+45,000$111,600→ 70,000 total
Sale
Common Stock
[F1][F2]
2026-02-17$26.17/sh−45,000$1,177,862→ 25,000 total
Exercise/Conversion
Stock Option (right to buy)
[F1][F3]
2026-02-17−45,000→ 221,268 total
Exercise: $2.48Exp: 2031-06-17→ Common Stock (45,000 underlying)

Footnotes (3)

[F1]The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
[F2]This transaction was executed in multiple trades at prices ranging from $25.76 to $26.695. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
[F3]All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Signature

/s/ Ben Hohl, by power of attorney|2026-02-19

1 file